menu
    • menu
    [{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Samarium-153 DOTMP","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ National Cancer Institute"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Samarium-153 DOTMP","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Samarium-153 DOTMP","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ Telix Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by QSAM Biosciences

    Menu

    QSAM Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            QSAM Biosciences

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            QSAM Biosciences

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samarium-153 DOTMP

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : $123.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Telix Signs Agreement to Acquire QSAM Biosciences and its Bone Cancer Targeting Platform

                            Details : Through the acquisition, Telix Pharmaceuticals have access to lead investigational drug Cycloslam (samarium-153-DOTMP) for therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

                            Product Name : CycloSam

                            Product Type : Other Small Molecule

                            Upfront Cash : $33.1 million

                            July 02, 2024

                            Lead Product(s) : Samarium-153 DOTMP

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : $123.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            QSAM Biosciences

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            QSAM Biosciences

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samarium-153 DOTMP

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : $125.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Telix Announces Proposed Acquisition of QSAM Biosciences and its Lead Therapy Candidate, CycloSam®

                            Details : Through the acquisition, Telix gain rights to CycloSam (samarium-153-DOTMP), a novel, de-risked clinical asset that has the potential to deliver tangible improvements of prior bone-seeking agents.

                            Product Name : CycloSam

                            Product Type : Other Small Molecule

                            Upfront Cash : $2.0 million

                            November 13, 2023

                            Lead Product(s) : Samarium-153 DOTMP

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : $125.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            QSAM Biosciences

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            QSAM Biosciences

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samarium-153 DOTMP

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam

                            Details : Patent covers both formulation and preparation of Samarium-153-DOTMP (CycloSam®), in U.S. with DOTMP kit formulations for radioisotope delivery targeting bone tumors, as well high-dosage use of radiopharmaceutical to perform bone marrow ablations.

                            Product Name : CycloSam

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 13, 2022

                            Lead Product(s) : Samarium-153 DOTMP

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth